Search details
1.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
BMC Neurol
; 14: 220, 2014 Nov 26.
Article
in English
| MEDLINE | ID: mdl-25424122
2.
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study.
Brain Commun
; 5(1): fcad026, 2023.
Article
in English
| MEDLINE | ID: mdl-36861013
3.
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States.
Neurol Ther
; 12(3): 849-861, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37000386
4.
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial.
Brain Commun
; 4(6): fcac300, 2022.
Article
in English
| MEDLINE | ID: mdl-36519155
5.
Digital Scientific Platform for Independent Content in Neurology: Rigorous Quality Guideline Development and Implementation.
Interact J Med Res
; 11(1): e35698, 2022 Jun 09.
Article
in English
| MEDLINE | ID: mdl-35485280
6.
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.
Neurol Ther
; 10(2): 803-818, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34165694
7.
Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate.
Curr Med Res Opin
; 36(7): 1167-1175, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32329362
8.
Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Clin Ther
; 42(11): 2136-2147.e3, 2020 11.
Article
in English
| MEDLINE | ID: mdl-33160682
9.
Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.
Neurol Ther
; 8(2): 185-205, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-31273563
10.
Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine.
Neurol Ther
; 7(1): 37-49, 2018 Jun.
Article
in English
| MEDLINE | ID: mdl-29222700
11.
Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Patient Education.
Neurol Ther
; 7(1): 23-36, 2018 Jun.
Article
in English
| MEDLINE | ID: mdl-29243028
12.
Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
J Neurol Sci
; 388: 168-174, 2018 05 15.
Article
in English
| MEDLINE | ID: mdl-29627016
13.
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
J Pharm Pract
; 31(5): 481-488, 2018 Oct.
Article
in English
| MEDLINE | ID: mdl-28847230
14.
Effectiveness of alternative dose fingolimod for multiple sclerosis.
Neurol Clin Pract
; 8(2): 102-107, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29708225
15.
Two decades of glatiramer acetate: From initial discovery to the current development of generics.
J Neurol Sci
; 376: 255-259, 2017 May 15.
Article
in English
| MEDLINE | ID: mdl-28431621
16.
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.
CNS Neurol Disord Drug Targets
; 16(6): 714-723, 2017.
Article
in English
| MEDLINE | ID: mdl-28240190
17.
Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial.
Lancet Neurol
; 16(9): 691-700, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28642125
18.
Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes.
J Pain
; 16(12): 1300-1311, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26409117
19.
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
Postgrad Med
; 127(2): 218-22, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25560174
20.
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.
PLoS One
; 10(10): e0140299, 2015.
Article
in English
| MEDLINE | ID: mdl-26473741